A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany (DELPHIN)

Bristol-Myers Squibb (BMS)

Status: Active, not recruiting

Conditions: Plaque Psoriasis

Treatments: Drug: Deucravacitinib

Study type: Observational

Funder types: Industry

Identifiers

NCT06104644

IM011-250

Details and patient eligibility

About

The purpose of this observational study is to describe the effectiveness of deucravacitinib treatment and quality of life in adults with moderate-to-severe plaque psoriasis in routine clinical practice in Germany over a 5-year period

Enrollment: 550 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with a physician-reported diagnosis of moderate-to-severe plaque psoriasis initiating deucravacitinib according to approved label in the European Union
• The decision upon treatment with deucravacitinib must have been made before enrollment and independently of this non-interventional observational study
• Patient is at least 18 years of age at the time of treatment decision
• Patient provided written informed consent to participate in the study

Exclusion criteria

• Any contraindications according to the approved deucravacitinib Summary of Product Characteristics
• Prior treatment with deucravacitinib
• Simultaneous participation in an interventional clinical trial for moderate-to-severe psoriasis

Trial design

550 participants in 1 patient group

Moderate-to-severe plaque psoriasis

Treatment:

Drug: Deucravacitinib